Kailera's Initial Public Offering#
Kailera Therapeutics Inc. (KLRA) has successfully completed its initial public offering (IPO), raising a total of $718.8 million. The company sold 44,921,875 shares of common stock at a price of $16.00 per share.
Details of the Offering#
The IPO included the full exercise of an option for underwriters to purchase an additional 5,859,375 shares. Importantly, all shares were offered directly by Kailera, meaning there were no existing shareholders selling their stakes in this transaction.
Trading on Nasdaq#
Kailera's stock is now trading on the Nasdaq Global Select Market under the ticker symbol KLRA. The company specializes in developing treatments for obesity and is currently in advanced stages of clinical development for its products.
Underwriters and Regulatory Approval#
The offering was managed by several financial institutions, including J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, and Evercore ISI, who acted as joint book-running managers. William Blair served as the lead manager. The Securities and Exchange Commission (SEC) approved the company's registration statement on Form S-1 on April 16, 2026, and the offering was completed on April 20, 2026, as stated in a press release.